“La Sexta Columna” television programme has broadcasted a report about the initiative taken by families with relatives that suffer from Friedreich’s Ataxia, a rare illness with no cure. Joined in an association called Genefa, these families raised the funds necessary to launch a research project – involving IRB Barcelona - to find a treatment.
The programme featured Juan Carlos Baiges, head of the association, Meritxell Teixidó, partner researcher in the Peptide and Protein Laboratory at IRB Barcelona, and Javier López Nido, researcher at the Severo Ochoa Centre of Molecular Biology in Madrid, with whom Teixidó works in coordination to carry the project forward.
Interview with Teresa Tarragó, co-founder together with Ernest Giralt of the spin-off Iproteos, about the discovery of new drugs for diseases that affect the central nervous system.
Tarragó explains the scope for biotech business opportunities is very big. "The projects have great potential but require a lot of funding. During the valorisation, spin-offs need more support, " says Tarragó. The IRB Barcelona researchers states that in Catalonia there are lots of good ideas but that "if we want more technology transfer we will have to make it carry greater weight when evaluating a researcher’s scientific production."
Extensive article published in Sunday’s issue of ARA on the research line developed by Meritxell Teixidó in Ernest Giralt’s lab to extract natural poison from bees, scorpions and spiders, which provides peptides able to cross the blood-brain barrier. Many drugs cannot enter the brain because of this barrier, which serves to protect this organ against infections. Several projects at IRB Barcelona seek to find and modify natural peptide venoms that have the capacity to cross this barrier without damaging it, in order to use them as drug transporters into the brain.
Extensive report on three "crowdfunding" initiatives, among them one led by
the company Iproteos, co-funded by researchers at IRB Barcelona.
Extensive article about the various research projects undertaken by Ernest Giralt’s group at IRB Barcelona. The article focuses on those devoted to the design of peptides with the capacity to cross the blood-brain barrier. “I think we are the only group worldwide studying the use of poisons as transporters of new drugs into the brain,” explains Ernest Giralt, full professor of the UB and coordinator of the Chemistry and Molecular Pharmacology Programme at IRB Barcelona.
Diario Médico reports on a study by Ernest Giralt’s lab (two pages) published in the Journal of Controlled Release on the design of a peptide capable of eliminating tumour cells. The peptide in question exploits the properties of wasp venom.
The company Iproteos, a spin-off from IRB Barcelona cofounded by Ernest Giralt and Teresa Tarragó, both researchers at IRB, has already surpassed 80% of the funding requested in a fundraising campaign that was launched in mid 2014. This news is echoed in El Periódico de Catalunya. The objective is to finance a drug for the treatment of schizophrenia.
Natàlia Carulla, associate researcher at IRB Barcelona devoted to studying
the aggregation of the protein beta-amyloid, which is strongly associated
with Alzheimer's disease, explains her approach to reveal the role of this
protein in this neurodegenerative disease, a condition that affects millions
of elderly people worldwide.
In a study recently published in ACS Chemical Biology, Carulla describes the
aggregation structures of beta-amyloid that are toxic for neurons.
The North American journal GEN reports on research performed by Natàlia Carulla, with the Peptides and Proteins Group at IRB, on beta-amyloid aggregates and their relation with Alzheimer’s disease. The study concludes that the most harmful aggregates for neurons are intermediate accumulations of beta-amyloid, these ranging from between 20 and 100 units.
IProteos, a spin-off from IRB Barcelona labs and co-funded by the researchers Teresa Tarragó and Ernest Giralt, has received the prize Expoquimia R+D+I for a new drug under development for the treatment of schizophrenia.